anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Loss of muscle mass is a normal consequence of aging in many older adults, worsened by chronic illness, poor appetite and diet, and reduced physical activity. The ensuing decline in physical function is a major cause of frailty, disability and death. Treatments that can reverse or reduce the age-associated loss of muscle mass are therefore much needed. Evidence is emerging that consumption of fish or fish oil derived long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) may be important for maintenance of muscle mass and physical function throughout the life-span. However, the effect of LCn-3PUFA supplementation on muscle mass, muscle strength and overall physical function is not known. The goal of this study therefore is to determine the effect of LCn-3PUFA supplementation on muscle mass, muscle strength and physical function in older adults.
Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain that temporarily disrupt normal brain function. Seizures are classified as "generalized," originating in both sides of the brain simultaneously, or "partial-onset," starting in one area of the brain. Antiepilepsy medications, such as topiramate, are selected based on seizure type. This study is designed to study patients with partial epilepsy. This is a double-blind, placebo-controlled study that includes a baseline phase and a treatment phase. During the baseline phase (8 weeks duration), patients receive one or two standard antiepileptic drugs (AEDs), such as phenytoin, carbamazepine, phenobarbital, primidone, or valproic acid. Patients who continue to have seizures during treatment with standard AEDs proceed into the double-blind treatment phase. Patients then receive topiramate or placebo at a dosage of 100-milligrams (mg) once daily, increasing gradually to 3 tablets twice daily (600 mg/day, maximum) for 12 weeks (total duration of double-blind phase), while continuing on their standard AED regimen. Assessments of effectiveness include the percent reduction in the average monthly seizure rate, percent of patients responding to treatment (having equal to or greater than 50% reduction in seizure rate), and the patient's and investigator's global assessments of medication at end of study. Safety assessments include the incidence of adverse events throughout the study, clinical laboratory tests (hematology, serum chemistry, urinalysis), neurologic examinations, and vital sign measurements (blood pressure, pulse, temperature) weekly during the treatment phase. The study hypothesis is that topiramate, taken as add-on therapy to treatment with AEDs, will significantly reduce seizure frequency, compared with placebo, in patients with refractory partial epilepsy: that is, in patients who continue to have seizures despite treatment with a first-line AEDs. In addition, it is hypothesized that topiramate is well-tolerated. Topiramate, 100 milligrams (mg) oral tablets. Dosage begins at 100 mg once daily and increases gradually over 4 weeks to 3 tablets twice daily (600 mg/day, maximum) or maximum tolerated dose for an additional 8 weeks.
The invention discloses a heart reinforcing, blood enriching, stomach tonifying and energy invigorating beverage electuary and a preparation method thereof. The beverage electuary is prepared from pine mushroom extract, common morel extract, white granulated sugar (when abdominal fullness and distention symptoms appear), starch, microcrystalline cellulose and dextrin. The preparation method comprises the following steps: preprocessing the above raw materials, proportioning the preprocessed raw materials, mixing the proportioned raw materials, granulating the obtained mixture, drying the granulated mixture, straightening the dried granules, and packaging the granules to obtain the beverage electuary. The beverage electuary contains the pine mushroom extract and the common morel extract, so the nutritional and functional effects of the beverage electuary are enhanced, and the beverage electuary has good health efficacy of heart reinforcing, blood enriching, stomach tonifying and energy invigorating. High quality pine mushroom and common morel are carefully chosen, and the white granulated sugar, starch, microcrystalline cellulose and dextrin are added to prepare the beverage electuary, so medicine effects of all above medicines have synergism, and the prepared granules are plump and have high solubility. The beverage electuary can reach the target effect, and can be used for a long term to realize the efficacy of heart reinforcing, blood enriching, stomach tonifying and energy invigorating.
Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
In order to effectively reach underserved women and reduce breast cancer disparities, D\&I efforts should target the healthcare delivery system where these women receive service - the so called "safety net". Within the safety net, federally qualified health centers (FQHCs), provide comprehensive primary health care services for underserved communities regardless of ability to pay, including mammography screening. Our team has successfully pilot tested a National Cancer Institute research tested intervention program (RTIP) with underserved women and were able to reduce no-show rates from 44% to 19%. In order to accelerate the adoption and implementation of our EBI within the safety net, the investigators will use a two-step approach based on the consolidated framework for implementation research (CFIR), and intervention mapping. The investigators will actively disseminate the EBI through a unique breast health collaborative with a wide membership of FQHCs, support implementation through training and evaluate the adoption, implementation, sustainment and effectiveness of the EBI. The investigators will use a clinic clustered stepped wedge design for implementation in FQHCs.
Our previous study found that receptor interacting protein 3 (RIP3) and apoptosis-inducing factor (AIF) were involved in neuronal programmed necrosis during global cerebral ischemia-reperfusion (I/R) injury. Here, we further studied its downstream mechanisms and the role of the autophagy inhibitors 3-methyladenine (3-MA) and bafilomycin A1 (BAF). A 20-min global cerebral I/R injury model was constructed using the 4-vessel occlusion (4-VO) method in male rats. 3-MA and BAF were injected into the lateral ventricle 1 h before ischemia. Spatial and activation changes of proteins were detected by immunofluorescence (IF), and protein interaction was determined by immunoprecipitation (IP). The phosphorylation of H2AX (γ-H2AX) and activation of mixed lineage kinase domain-like protein (p-MLKL) occurred as early as 6 h after reperfusion. RIP3, AIF, and cyclophilin A (CypA) in the neurons after I/R injury were spatially overlapped around and within the nucleus and combined with each other after reperfusion. The survival rate of CA1 neurons in the 3-MA and BAF groups was significantly higher than that in the I/R group. Autophagy was activated significantly after I/R injury, which was partially inhibited by 3-MA and BAF. Pretreatment with both 3-MA and BAF almost completely inhibited nuclear translocation, spatial overlap, and combination of RIP3, AIF, and CypA proteins. These findings suggest that after global cerebral I/R injury, RIP3, AIF, and CypA translocated into the nuclei and formed the DNA degradation complex RIP3/AIF/CypA in hippocampal CA1 neurons. Pretreatment with autophagy inhibitors could reduce neuronal necroptosis by preventing the formation of the RIP3/AIF/CypA complex and its nuclear translocation.
<P>PROBLEM TO BE SOLVED: To provide a use of a natural human α-interferon, a neuraminidase inhibitor, and ribavirin, for the purpose of treating avian influenza.  <P>SOLUTION: In this use, effects of an influenza virus are mitigated with a dsRNA in combination together with the neuraminidase influenza virus inhibitor. Two of products comprising the dsRNA and the α-interferon are preventively (prophylactically) or therapeutically administered, or therapeutically useful in treatment of disease which is developed. The unique immunological/antiviral actions which operate through immunological "cascades" improve a lethal effect of viral mutation which sharply accelerates a death rate, by causing resistance to commonly available medicaments. About 40 million people were, for example, caused to die by the avian influenza worldwide in 1918-1920 (ref. National Geographic, September 2005).  <P>COPYRIGHT: (C)2007,JPO&INPIT
Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
Detergent compositions comprise (a) a surface-active substance and (b) an ester of a boric acid with a fatty acid alkanolamide or with a mixture of a fatty acid alkanol-amide and an alcohol, the boric acid being completely esterified and containing at least one alkanolamide residue per boron atom; the fatty acid alkanolamide is preferably one containing 10-20 carbon atoms in the fatty acid chain and up to 5 carbon atoms in the alkanol residue.  Component (a) may be a soap derived from natural or synthetic fatty acids, an ethercarboxylate, the condensate of a fatty acid with an amino acid or with a protein hydrolysis product, an alkyl- or cycloalkyl-sulphonate, an alkyl- or cycloalkyl-aryl sulphonate, a fatty acid ester of a hydroxyalkyl sulphonate, a condensate of a fatty acid with an aminoalkyl sulphonate, an alkyl sulphate, a sulphated partial ester of a fatty acid with a polyhydric alcohol, a sulphated partial ether of a fatty alcohol with a polyhydric alcohol, a sulphated fatty alcohol polyglycol or polyglycerol ether, a sulphated fatty acid alkanolamide, a polyethylene glycol, or a mixed polyether.  The amount of (b) present should not be more than that of (a) and is generally less.  The compositions may also include alkali metal phosphate, polyphosphate, sulphate, silicate, perborate, carbonate and bicarbonate, magnesium sulphate and silicate, carboxymethyl cellulose paraffins, fatty acids, alcohols, esters, especially glycerides, lanolin, lecithin, titanium dioxide, kaolin, bentonite, colloidal silica, boric acid, urea, 3 : 5 : 6 : 31 : 51 : 61 - hexachloro - 2 : 21 - dihydroxydiphenylmethane, perfume, optical brightners, deodorants, dyestuffs and disinfectants.  The compositions may be produced in bar, powder, chip, noodle or flake form by conventional methods, the boric acid ester, which preferably has a melting point of 65-110 DEG  C., being suitably added in a molten state to a paste of the surface-active substance.  In one embodiment, an ethylene oxide reaction product with a fatty alcohol, a fatty acid or an alkylphenol is melted together with the ester (b), and the melt is allowed to harden in moulds to form sticks which are suitable for use in removing fat stains from textiles of polyamide fibres.ALSO:Borate esters of fatty acid alkanolamides are obtained by heating boric acid (H3BO3) or an anhydride thereof, e.g. HBO2, H2B4O7 or B2O3, with the fatty acid alkanolamide or with a mixture of a fatty acid alkanolamide and an alcohol, so that the boric acid is completely esterified and contains at least one alkanolamide residue per boron atom; the fatty acid alkanolamide is preferably one containing 10-20 carbon atoms in the fatty acid chain and up to 5 carbon atoms in the alkanol residue, and the reaction is carried out preferably at 80-160 DEG  C.  The water formed may be removed by the passage of inert gas, by boiling inert solvents, or directly at the upper range of reaction temperature.  The esters may also be obtained by inter-esterifying boric acid esters with fatty acid alkanolamides.
The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are \>=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, \>=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
<P>PROBLEM TO BE SOLVED: To provide an adhesive film for use in adhesion, above all in medical treatment, and a method for producing an adhesive film which can be suitably utilized as an implant adhesive film.  <P>SOLUTION: The adhesive film has a honeycomb structure and is mainly composed of a biodegradable polymer containing 1-40 mol.% caprolactone component as a copolymer component. Furthermore, the adhesive film having a honeycomb structure further comprises 0.01-100 pts.wt. phospholipid based on 100 pts.wt. biodegradable polymer.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This is a phase II open-label study. Patients will be screened for MPN diagnoses and patients with Polycythemia vera proven to have JAK2V617F mutation will be given the option to enroll. Consenting patients will take erlotinib daily for 16 weeks. Blood work and pharmacokinetics will be drawn for serum level monitoring. Doses will be administered according to side effects or held. First assessment will be at day 15 wth subsequent assessments at 28 day intervals. Non-responders will be taken off the study and managed according to standard of care. Patients who do respond will continue taking the therapy for a total of 12 months. Observation will be for a total of 12 months after finishing treatment. In addition to the clinical aspect of this study, there will be correlative studies where molecular response will be checked and its correlation with clinical response.
A total of three sub-projects will be conducted in this project. Sub-project 1 will establish a pre-clinical rat model for lymphedema and develop novel MRI methods, including diffusion kurtosis MRI and free water elimination diffusion MRI techniques, for mapping tissue characteristics of lymphedema. Sub-project 1 will be complemented with the clinical images provided by sub-project 2, yielding more information about the lymphedema. Sub-project 2 aims to optimize the clinical MRI methods for mapping lymphedema and quantitatively assess the severity of lymphedema. A normal imaging database will be established for reference. Sub-project 2 and sub-project 3 will be complementary in co-developing the image assessment of post-surgical therapeutic effect. Sub-project 3 will quantitatively evaluate the severity of lymphedema secondary to different kinds of axillary treatments by using the clinical MRI methods for establishing longitudinal monitoring and prediction approaches. It also focuses on the pre-surgical and post-surgical evaluation of lymphedema undergone supermicrosurgical technique by using the clinical MRI methods.
BACKGROUND: Arthroplasty registries often use traditional Medicare (TM) claims data to report long-term total hip arthroplasty (THA) survivorship. The purpose of this study was to determine whether the large number of patients leaving TM for Medicare Advantage (MA) has compromised the fidelity of TM data.
METHODS: We identified 10,962 THAs in 9,333 Medicare-eligible patients who underwent primary THA from 2000 to 2020 at a single institution. Insurance type was analyzed, and 83% of patients had TM at the time of THA. Survivorship free from any revision or reoperation was calculated for patients who have TM. The same survivorship end points were recalculated with censoring performed when a patient transitioned to an MA plan after their primary THA to model the impact of losing patients from the TM dataset. Differences in survivorship were compared. The mean follow-up was 7 years.
RESULTS: From 2000 to 2020, there was a decrease in TM insurance (93 to 73%) and a corresponding increase in MA insurance (0 to 19%) among THA patients. Following THA, 23% of TM patients switched to MA. For patients who had TM at the time of surgery, 15-year survivorship free from any reoperation or revision was 90% and 93%, respectively. When censoring patients upon transition from TM to MA, survivorship free from any reoperation became significantly higher (92 versus 90% at 15 years; hazard ratio = 1.16, P = .033), and there was a trend toward higher survivorship free from any revision (95 versus 93% at 15 years; hazard ratio = 1.16, P = .074).
CONCLUSIONS: Approximately 1 in 4 patients left TM for MA after primary THA, effectively making them lost to follow-up within TM datasets. The mass exodus of patients out of TM appears to have led to a slight overestimation of survivorship free from any reoperation and trended toward overestimating survivorship free from any revision. If MA continues to grow, efforts to obtain MA data will become even more important.
Although patients with chronic kidney disease (CKD) have a higher risk of colorectal cancer (CRC) aggravation, the connection between these two diseases is not well understood. Recent studies have shown that both CKD and CRC aggravation are closely related to an increased abundance of indole-producing Fusobacterium nucleatum in the gut. The indole absorbed from the gut is eventually metabolized to indoxyl sulfate in the liver. Since indoxyl sulfate is involved not only in accelerating CKD progression but also in the initiation and development of its associated complications, the present study aimed to clarify whether indoxyl sulfate induces the proliferation of CRC cells. This study found that indoxyl sulfate induced the proliferation of CRC-derived HCT-116 cells by activating the aryl hydrocarbon receptor (AhR) and the proto-oncogene Akt. The AhR antagonist CH223191 and Akt inhibitor MK2206 suppressed indoxyl sulfate-induced proliferation of HCT-116 cells. We also found that indoxyl sulfate upregulated epidermal growth factor receptor (EGFR) expression, which is associated with poor prognosis of CRC, whereas CH223191 and MK2206 repressed EGFR expression. Furthermore, indoxyl sulfate increased the sensitivity of CRC cells to EGF by upregulating EGFR expression. These findings suggest that indoxyl sulfate may be an important link between CKD and CRC aggravation.
The process comprises (a) hydrogenating a tabersonine salt soln. with hydrogen in presence of Raney Ni at 25-50 deg.C under 8-30 atmos. to give vincadifformine (b) forming the salt with an acid to block the tert. N atom and prevent formation of the N-oxide (c) oxidising with a solid mixt. of maleic and permaleic acids, at -10 to 5 deg.C for 1-1.5 hrs. to give 3-oxy vincadifformine (d) heating a soln. of this at 30-50 deg.C for 2-4 hrs. to give apovincamine, epivincamine and vincamine (e) precipitating with ammonia and (f) filtering to isolate the vincamine.
The MIEC will be conducted on a cycle ergometer (Excalibur, Lode, Groningen, The Nederlands) in normoxia (FiO2 = \~ 21%). The participants will be instructed to resist against the pedal movement (cadence set at 15 revolutions/min) to produce the required torque (set to obtain the 75-80%HRmax) indicated by visual feedback for 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age. The HR responses will be monitored (Polar Electro Oy, Kempele, Finland).
This invention relates to methods of preventing or reducing the severity of diabetes. In one embodiment, the method involves administering to the individual a peptide having substantially the sequence of a non-conserved region sequence of a T cell receptor present on the surface of T cells mediating diabetes or a fragment thereof, wherein the peptide or fragment is capable of causing an effect on the immune system to regulate the T cells. In particular, the T cell receptor has the V.beta. regional V.beta.6 or V.beta.14. In another embodiment, the method involves gene therapy. The invention also relates to methods of diagnosing diabetes by determining the presence of diabetes predominant T cell receptors.
Human studies reported by SJ Holmes et al, 1993, AM Richards et al, 1993 and M. Yoshimara et al, 1991 show that administration of externally produced hBNP produces vasodilation; antagonism of the hormone system that helps regulate long term blood pressure and blood volume in the body; and an increase in urine output containing large amounts of salt. These studies suggest hBNP may be a potent agent for the treatment of acute congestive heart failure (CHF) with a unique combination of desirable effects on the flow of blood throughout the body; the hormones secreted by the nervous system; and support of copious salt outputs by the renal system not provided by currently available therapies. Plasma hBNP levels are elevated in CHF and hBNP may be one of the body's natural compensatory mechanisms to augment cardiac functions in a failing heart. NATRECOR® hBNP is Scios' proprietary form of hBNP and it is identical to the amino acid sequence in the naturally occurring hormone. This is a randomized, double-blinded, placebo-controlled, multicenter study to determine the efficacy of two distinct doses of NATRECOR® hBNP in patients with symptomatic, decompensated congestive heart failure to decrease pulmonary capillary wedge pressure, as measured by a blinded comparison to placebo after 6 hours of treatment. Patients are randomized to receive either a placebo or one of two doses (0.015 or 0.03 µg/kg/min) of NATRECOR® hBNP. The study hypothesis is that NATRECOR ® hBNP is well tolerated and an effective agent for the short-term management of hospitalized patients with symptomatic, decompensated CHF. Patients are randomized to receive either a placebo or one of two doses (0.015 or 0.03 µg/kg/min) of NATRECOR® hBNP. Doses are administered one time only, an intravenous loading bolus, followed by continuous intravenous infusion for 6 hours.